{"disease":{"id":"glycogen-storage-disease-type-ii","name":"glycogen storage disease type ii"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00231400","title":"Pompe Disease Registry Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT02782741","title":"Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT02765828","title":"Identification of Tongue Involvement in Late-Onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05017402","title":"Higher Dose of Alglucosidase Alpha for Pompe Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT06130228","title":"Nutritional Therapy in Late-onset Pompe Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT01898364","title":"Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT03019406","title":"A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT02801539","title":"Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT01410890","title":"Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT00567073","title":"Pompe Pregnancy Sub-Registry","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT05951790","title":"Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fondazione Don Carlo Gnocchi Onlus","has_results":false},{"nct_id":"NCT02032524","title":"Avalglucosidase Alfa Extension Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT04574830","title":"Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT04910776","title":"Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05164055","title":"Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT04848779","title":"A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05196165","title":"Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT06666413","title":"China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":13,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT00486889","title":"Growth and Development Study of Alglucosidase Alfa","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT03687333","title":"Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT06575829","title":"Treatment Frequency Reduction in Pompe Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04990388","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT00701701","title":"Immune Tolerance Induction Study","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT02363153","title":"Diet and Exercise in Pompe Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT02385162","title":"Biomarker for Glycogen Storage Diseases (BioGlycogen)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}